Bone Metastases: Are We Failing Our Patients?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G
. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2008; 20(1):137-45.
DOI: 10.1093/annonc/mdn526.
View
2.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J
. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2005; 67(5-6):390-6.
DOI: 10.1159/000082923.
View
3.
Saad F, Chen Y, Gleason D, Chin J
. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007; 5(6):390-6.
DOI: 10.3816/CGC.2007.n.022.
View
4.
Dimopoulos M, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M
. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2008; 20(1):117-20.
DOI: 10.1093/annonc/mdn554.
View
5.
Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Yardley D
. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012; 48(16):3082-92.
DOI: 10.1016/j.ejca.2012.08.002.
View